10-Q: Teleflex Q3 Loss Hits $408.9M Amid Goodwill Impairment

Teleflex Incorporated reported a significant net loss of $408.9 million for the third quarter of 2025, primarily driven by a $403.9 million goodwill impairment charge related to its Interventional Urology North America unit and a $100 million asset impairment for the Titan SGS product line.

Summary

• Reported a net loss of $408.9 million for the three months ended September 28, 2025, a significant decline from net income of $111.0 million in the prior year period.
• Reported a net loss of $191.3 million for the nine months ended September 28, 2025, compared to net income of $206.3 million in the prior year period.
• Recognized a goodwill impairment charge of $403.9 million related to the Interventional Urology North America (IU) reporting unit for the three and nine months ended September 28, 2025.
• Recognized an asset impairment charge of $100.0 million related to the Titan SGS asset group for the three and nine months ended September 28, 2025.
• Net revenues increased by 19.4% to $913.0 million for the three months ended September 28, 2025, and by 6.3% to $2,394.6 million for the nine months ended September 28, 2025.
• Revenue growth was primarily driven by the acquisition of the Vascular Intervention (VI) Business, contributing $101.8 million in post-acquisition revenue for the nine months, and a $23.7 million favorable impact from a decrease in Italian payback measure reserves.
• Gross profit decreased to 49.5% of sales for the three months and 53.1% for the nine months, down from 56.3% and 56.1% respectively, primarily due to VI Business acquisition-related amortization and tariffs.
• Completed the acquisition of substantially all of BIOTRONIK SE & Co. KG's Vascular Intervention business for $825.2 million on June 30, 2025.
• Announced a strategic decision to separate into two independent companies, with a potential sale of 'NewCo' (Acute Care, Interventional Urology, and OEM businesses) as the primary focus.
• Incurred $32.1 million in separation costs for the nine months ended September 28, 2025.
• The Board approved a new VI Business Integration plan in Q4 2025, with estimated restructuring charges of $36 million to $44 million and expected annual pre-tax savings of $24 million to $30 million by the end of 2028.

Sentiment

Score: 3

Explanation: The significant net loss driven by substantial impairment charges (goodwill and asset) indicates severe underperformance in key segments. While revenue growth from acquisitions is positive, the erosion of gross margin due to tariffs and integration costs, coupled with a decline in operating cash flow, points to considerable financial headwinds and operational challenges. The strategic separation and integration plans introduce further uncertainty, despite potential future savings.

Positives

• Net revenues increased by 19.4% ($148.6 million) for the three months ended September 28, 2025, and by 6.3% ($142.7 million) for the nine months ended September 28, 2025.
• The acquisition of the Vascular Intervention (VI) Business contributed $101.8 million in post-acquisition revenue for the nine months ended September 28, 2025.
• A favorable impact of $23.7 million resulted from a decrease in reserves related to the Italian payback measure for the three and nine months ended September 28, 2025.
• Favorable fluctuations in foreign currency exchange rates contributed $10.0 million to net revenues for the three months and $9.5 million for the nine months.
• A $9.4 million favorable impact was realized from a stocking order in China related to initiatives to expand the sales channel of intra-aortic balloon pumps and catheters.
• Net cash provided by operating activities from continuing operations was $189.0 million for the nine months ended September 28, 2025.
• Successfully hedged foreign currency exposure for the VI Business acquisition, resulting in $82.2 million in proceeds from settled forward contracts.
• Expected annual pre-tax savings of $24 million to $30 million are anticipated from the VI Business Integration plan once fully implemented by the end of 2028.
• The average interest rate on debt decreased to 4.1% for the nine months ended September 28, 2025, compared to 4.5% in the prior year.

Negatives

• Reported a net loss of $408.9 million for the three months ended September 28, 2025, compared to net income of $111.0 million in the prior year.
• Reported a net loss of $191.3 million for the nine months ended September 28, 2025, compared to net income of $206.3 million in the prior year.
• Incurred a goodwill impairment charge of $403.9 million related to the Interventional Urology North America (IU) reporting unit.
• Recognized an asset impairment charge of $100.0 million related to the Titan SGS asset group due to lower than expected sales and reduced demand for bariatric surgery procedures.
• Gross margin significantly decreased to 49.5% for the three months (from 56.3%) and 53.1% for the nine months (from 56.1%).
• Gross margin decline was attributed to the amortization of the step-up in inventory and intangible assets from the VI Business acquisition, recently enacted tariffs, increased logistics and distribution costs, and continued cost inflation (labor, raw materials).
• Selling, general and administrative expenses increased by $34.5 million for the three months ended September 28, 2025, primarily due to VI Business operating costs and intangible asset amortization.
• Net cash provided by operating activities decreased by $246.6 million for the nine months ended September 28, 2025, primarily due to unfavorable changes in working capital and operating results, tariffs, and higher tax payments.
• Experienced a $47.6 million decrease in sales volumes of existing products for the nine months, particularly in the OEM product category and UroLift product line.
• Asia operating profit decreased by 39.1% for the three months and 28.1% for the nine months, due to a decrease in gross profit, price decreases, unfavorable product mix, and increased VI Business operating costs.
• EMEA operating profit decreased by 20.4% for the three months due to increased VI Business operating costs and amortization impacts.
• Observed increased inventory levels of intra-aortic balloon pumps and catheters at some distributors in China, with slower than anticipated sales to third parties.

Risks

• The Interventional Urology North America (IU) reporting unit has been at risk of impairment, leading to a $403.9 million charge, driven by lower market multiples, higher stand-alone operating costs, and lower revenue growth.
• The Titan SGS asset group incurred a $100.0 million impairment due to lower than expected sales and anticipated continuing reduced demand for bariatric surgery procedures, driven by the growing adoption of GLP-1 products.
• There are no guarantees that the proposed strategic separation into two independent companies will be completed on the announced terms, timeframe, or at all.
• Recently enacted U.S. tariffs and retaliatory measures negatively impacted gross margins and cash flows, primarily due to higher import costs from EU operations and non-USMCA compliant products from Mexico, with additional changes potentially having a material negative impact.
• While a modification reduced payment amounts for the Italian payback measure for 2015-2018, a reserve of $18.3 million remains for 2019-2025, indicating ongoing exposure.
• Increased inventory levels of intra-aortic balloon pumps and catheters at Chinese distributors, with slower than anticipated sales, could adversely impact future results if demand does not increase or expansion efforts fail.
• A foreign tax authority denied the request for reassessment of Palette's previously filed tax returns, and if unsuccessful in appeal, the company may be required to pay an amount in excess of the current $4.4 million liability, which could be material.
• Various lawsuits and claims (product liability, intellectual property, etc.) could, if unfavorable, be materially adverse to business, financial condition, results of operations, or liquidity.
• Integrating the acquired VI Business involves realignment of the sales force, administrative functions, manufacturing operations, and workforce reductions, which carries execution risks.
• Continued cost inflation from macro-economic factors, specifically with respect to labor and raw materials, and increased logistics and distribution costs, pose ongoing challenges.

Future Outlook

Anticipates revenue growth from the Titan SGS asset group in future periods despite recent downward revisions to sales forecasts. Expects to achieve annual pre-tax savings of $2 million to $4 million from the 2023 Footprint realignment plan once fully implemented by the end of 2027. The newly approved VI Business Integration plan is expected to generate annual pre-tax savings of $24 million to $30 million once fully implemented by the end of 2028, with plan-related savings beginning in 2026. Evaluating options to mitigate tariff exposure through supply chain optimization strategies, including modifications to chain of custody protocols and increasing USMCA compliant products. The proposed separation into two independent companies, with a potential sale of 'NewCo,' is actively being advanced, though completion is not guaranteed.

Management Comments

• Focused on achieving consistent, sustainable and profitable growth by increasing market share and improving operating efficiencies.
• Evaluates its portfolio of products and businesses on an ongoing basis to ensure alignment with overall objectives.
• May identify opportunities to divest businesses and product lines that do not meet objectives.
• May seek to optimize utilization of facilities through restructuring initiatives designed to further improve cost structure and enhance competitive position.
• May continue to explore opportunities to expand the size of its business and improve operating margins through a combination of acquisitions and distributor to direct sales conversions.
• There can be no guarantees that the proposed separation will be completed on the terms and within the timeframe announced, or at all.
• Currently evaluating options to mitigate exposure through supply chain optimization strategies, including modifications to chain of custody protocols and increasing the proportion of products compliant with the USMCA in its portfolio, in addition to customer pricing.
• Strongly disagrees with the tax authority's decision regarding the Palette acquisition tax matter and is currently consulting with external legal and tax advisors to evaluate all available options, intending to defend the position stated in its reassessment request vigorously.
• Believes its cash flow from operations, available cash and cash equivalents and borrowings under its revolving credit facility will enable it to fund operating requirements, including those arising from newly implemented tariffs, capital expenditures, debt obligations and separation costs for the next 12 months and the foreseeable future.

Industry Context

The filing reflects broader industry trends such as consolidation through acquisitions (VI Business), strategic portfolio optimization (separation into two companies, divestiture considerations), and the impact of evolving healthcare technologies (GLP-1 products affecting bariatric surgery demand). The challenges faced with tariffs and the Italian payback measure highlight the increasing regulatory and geopolitical complexities for global medical device manufacturers. The company's focus on cost optimization through restructuring and supply chain adjustments is a common response to inflationary pressures and competitive markets within the medical technology sector.

Comparison to Industry Standards

• The impact of GLP-1 products on the demand for bariatric surgery procedures, leading to the Titan SGS asset impairment, reflects a significant shift in the medical device industry where pharmaceutical innovations can directly disrupt surgical markets. This is comparable to how new drug therapies have impacted other surgical specialties in the past.
• The strategy of separating into two independent companies to unlock value is a common corporate maneuver seen across various industries, including healthcare, where diversified conglomerates seek to create more focused entities to better compete and attract specialized investors.
• The challenges with the Italian payback measure are indicative of increasing government cost-containment efforts in national healthcare systems, a trend that affects all medical device companies operating in Europe. This is a recurring theme for companies like Medtronic, Johnson & Johnson, and Siemens Healthineers in their European operations.
• The acquisition of BIOTRONIK's Vascular Intervention business aligns with the industry trend of strategic M&A to expand product portfolios and gain market share in high-growth areas like interventional cardiology and peripheral vascular disease, similar to recent moves by Boston Scientific or Abbott Laboratories.

Corporate Governance

Legal Proceedings

• Environmental Matters: Subject to contingencies from environmental laws and regulations, with $0.5 million in accrued liabilities and $3.0 million in other liabilities as of September 28, 2025. Potential liability may exceed accrued amounts if adverse changes occur.
• General Lawsuits and Claims: Party to various lawsuits and claims (product liability, intellectual property, commercial disputes, etc.) with $1.9 million in accrued liabilities as of September 28, 2025. While not currently believed to be material, unexpected developments could be materially adverse.
• Italian Payback Measure: Faced invoices from Italian regions for excess medical device expenditures (2015-2018). Appeals challenging constitutionality were denied. Legislation modification in August 2025 reduced payment to approximately 25% of original invoiced amounts. Payment was remitted, settling 2015-2018. A reserve of $18.3 million remains for 2019-2025.
• Palette Acquisition Tax Matter: Identified foreign tax liabilities of $4.4 million related to Palette acquisition. Request for reassessment denied by tax authority in October 2025. The company intends to vigorously defend its position, but an unfavorable outcome could be material.
• Class Action Complaint (Harrison v. Teleflex Incorporated, et al.): A class action complaint filed on March 6, 2025, alleging a bylaw provision restricting stockholder written consent violated Delaware law. The company amended its bylaws on May 9, 2025, to remove the challenged provision, leading to the dismissal of the action as moot on August 5, 2025. A mootness fee of $55,000 was paid to plaintiffs' counsel.

Stakeholder Impact

• Shareholders: Significant net loss and impairment charges will negatively impact shareholder value and earnings per share. The strategic separation could create value or introduce uncertainty. Share repurchase program aims to return value.
• Employees: Restructuring plans (2023 Footprint realignment, VI Business Integration) involve workforce reductions and relocations, impacting employees in affected manufacturing and administrative functions.
• Customers: The acquisition of VI Business expands the interventional product portfolio, potentially offering a broader range of coronary and peripheral medical devices. Supply chain optimization efforts aim to mitigate tariff impacts, which could affect product availability or pricing.
• Suppliers: Supply chain optimization strategies and relocation of manufacturing operations may impact existing supplier relationships.
• Creditors: Increased long-term borrowings ($700 million delayed draw term loan, $140 million revolving credit facility) for the VI Business acquisition increases debt load, though the company believes it can fund operating requirements and debt obligations.

Next Steps

• Continue to actively advance the process for a potential sale of 'NewCo' (Acute Care, Interventional Urology, and OEM businesses).
• Substantially complete the 2023 Footprint realignment plan by the end of 2027.
• Implement the VI Business Integration plan, with actions expected to be substantially completed by the end of 2028.
• Realize plan-related savings from the VI Business Integration plan starting in 2026.
• Incur an estimated $12 million to $14 million in cash outlays for the VI Business Integration plan during 2026.
• Incur an estimated $5 million to $7 million in aggregate capital expenditures under the VI Business Integration plan mostly between 2026 and 2027.
• Evaluate all available options and vigorously defend the position regarding the Palette acquisition tax matter.
• Evaluate new FASB guidance on income tax disclosure requirements (effective after December 15, 2024) and expense disclosures (effective after December 15, 2026).
• Evaluate new FASB guidance on internal-use software (effective after December 15, 2027).
• Continue to evaluate options to mitigate tariff exposure through supply chain optimization strategies, including modifications to chain of custody protocols and increasing USMCA compliant products, in addition to customer pricing.

Key Dates

Recommendation

The filing reveals a deeply concerning financial performance, marked by a substantial net loss of $408.9 million in the quarter, primarily due to a $403.9 million goodwill impairment in Interventional Urology and a $100 million asset impairment for Titan SGS. These impairments signal fundamental issues with asset valuation and market demand in key segments, exacerbated by the growing adoption of GLP-1 products impacting bariatric surgery. While revenue growth from the VI Business acquisition is noted, it comes with significant integration costs, gross margin erosion (down to 49.5% from 56.3%), and increased debt. Operating cash flow also saw a substantial decline. The announced strategic separation, while potentially value-unlocking long-term, introduces near-term uncertainty and execution risk. The combination of significant losses, asset write-downs, margin pressure, and strategic upheaval suggests a challenging outlook, warranting a 'sell' recommendation for seasoned investors.

Keywords

Medical devices, SEC filing, 10-Q, Teleflex, TFX, Financial results, Goodwill impairment, Asset impairment, Vascular Intervention, BIOTRONIK, Strategic separation, Restructuring, Tariffs, Italian payback measure, Titan SGS, Interventional Urology, Medical technology, Healthcare, Quarterly report